StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

Cartesian Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Cartesian Therapeutics's enterprise value was $112.21M on Nov 10, 2026, against $51.38M a year earlier. Over the last 5 years it ranged from -$32.87M to $271.18M, with a median of $88.09M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 10, 2026$112.21M+154.4%
2025Dec 31, 2025$44.10M-78.9%
2024Dec 31, 2024$208.79M+670.7%
2023Dec 29, 2023$27.09M+2.3%
2022Dec 30, 2022$26.48M-88.9%
2021Dec 31, 2021$237.68M+33.0%
2020Dec 31, 2020$178.66M+122.0%
2019Dec 31, 2019$80.47M+785.4%
2018Dec 31, 2018$9.09M-91.9%
2017Dec 29, 2017$112.61M-51.6%
2016Dec 30, 2016$232.65M–

More Cartesian Therapeutics figures

See a number that looks wrong?